Healthcare Providers and Services
Company Overview of University Hospitals Cleveland Medical Center Inc.
University Hospitals Cleveland Medical Center Inc., doing business as University Hospitals Case Medical Center, operates a tertiary medical center specializing in adult/pediatric medical and surgical specialties. Its services include cancer care, digestive health care, heart and vascular care, neurology and neurosurgery, obstetrics and gynecology, ophthalmology and dermatology, orthopedics and spine, otolaryngology, pediatrics, surgery, transplant, and urology. The company also provides services in the areas of women’s health, radiology and radiation oncology, cardiology and cardiothoracic surgery, organ transplantation and infectious diseases, behavioral health, and human genetics and genom...
11100 Euclid Avenue
Cleveland, OH 44106
Founded in 1988
Key Executives for University Hospitals Cleveland Medical Center Inc.
President and Chief of Cardiovascular Medicine
President of The UH Seidman Cancer Center
Chairman of the Department of Pediatrics at Rainbow Babies & Children's Hospital
Compensation as of Fiscal Year 2015.
University Hospitals Cleveland Medical Center Inc. Key Developments
University Hospitals Case Medical Center Announces Executive Changes
Dec 14 15
University Hospitals Case Medical Center has appointed Daniel I. Simon, MD, as the academic medical center's new President effective Jan. 1, 2016. In a release, University Hospitals noted that Dr. Simon will succeed Fred C. Rothstein, MD, who announced his retirement this summer after serving as President of UH Case Medical Center. University Hospitals reported that Dr. Simon is a leader in the field of cardiology. He has enhanced the prominence of UH Harrington Heart & Vascular Institute, where he has served as Director since 2006 and as President since 2014.
University Hospitals Case Medical Center Announces Executive Changes, Effective Jan. 1, 2016
Dec 4 15
University Hospitals Case Medical Center has appointed Daniel I. Simon, MD, as the academic medical center's new President effective Jan. 1, 2016. Dr. Simon will succeed Fred C. Rothstein, MD, who announced his retirement this summer after serving as President of UH Case Medical Center and one of the leader at the health system for the past 12 years. Dr. Simon is a leader in the field of cardiology. His dynamic leadership qualities and collegial style have enhanced the prominence of UH Harrington Heart & Vascular Institute, where he has served as Director since 2006 and as President since 2014. Throughout his tenure, he and his team have developed and executed growth, business and clinical strategies to enhance patient access, clinical integration and quality outcomes. Additionally, he has served as Chief of the Division of Cardiovascular Medicine at UH Case Medical Center and Professor of Medicine at Case Western Reserve University School of Medicine. He also holds the Herman K. Hellerstein, MD, Chair in Cardiovascular Research at UH Case Medical Center and the School of Medicine. Dr. Simon is an active interventional cardiologist and continues to play a leading role in national and international clinical trials investigating new devices, anti-thrombotic drugs, and regenerative medicine/adult stem cell therapies.
University Hospitals Case Medical Center Presents New Results from Systolic Blood Pressure Intervention Trial
Nov 9 15
University Hospitals Case Medical Center presented new results from the Systolic Blood Pressure Intervention Trial (SPRINT) showing that in patients at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of fatal and non-fatal major events or death compared to targeting systolic blood pressure to the usually recommended target of less than 140 mm Hg. The findings presented at the American Heart Association (AHA) Scientific Sessions in Orlando and published in the New England Journal of Medicine (NEJM) add to the preliminary results from SPRINT announced two months ago. These findings demonstrated intensive management of high blood pressure, below a commonly recommended blood pressure target, significantly reduces rates of cardiovascular disease, and lowers risk of death in a group of adults 50 years and older with high blood pressure. The SPRINT study, a landmark clinical trial sponsored by the National Institutes of Health, has evaluated the benefits of maintaining a new target for systolic blood pressure, the top number in a blood pressure reading, among a group of patients 50 years and older at increased risk for heart disease or who have kidney disease. University Hospitals Case Medical Center/Case Western Reserve University School of Medicine coordinated one of the five Clinical Center Networks (CCNs) across the country selected to conduct the trial that has recruited more than 9,300 participants. This blood pressure intervention portion of the trial was stopped 3.26 years into a planned 5-year term as a result of the finding of a 25% reduction in the primary cardiovascular outcome and 27% reduction of all-cause mortality in those randomized to the lower 120 mm blood pressure target. Specifically, a 38% reduction in heart failure and 43% reduction in death from heart-related events was found and reported in NEJM. The study reported about 1% to 2% higher rates of adverse events such as hypotension, syncope, electrolyte abnormalities and acute kidney injury/failures in the group of patients treated to the lower systolic blood pressure target. As a continuation of these findings, SPRINT researchers are proceeding to examine how the lower systolic blood pressure target may impact the incidence of dementia and long-term kidney disease. In order to achieve the 120 mm target, the findings also noted that an average of one additional medication was required for the lower target with no difference in tolerability even in patients over age 75.
Similar Private Companies By Industry
Recent Private Companies Transactions